{
    "root": "46121457-8af5-4016-827f-ead2f0b33b83",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "dasatinib",
    "value": "20240910",
    "ingredients": [
        {
            "name": "DASATINIB",
            "code": "RBZ1571X5H"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "GLYCERYL MONO- AND DICAPRYLOCAPRATE",
            "code": "U72Q2I8C85"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "dasatinib tablets indicated treatment adult patients newly diagnosed philadelphia chromosome-positive ( ph+ ) chronic myeloid leukemia ( cml ) chronic phase . chronic , accelerated myeloid lymphoid blast phase ph+ cml resistance intolerance prior therapy including imatinib . philadelphia chromosome-positive acute lymphoblastic leukemia ( ph+ ) resistance intolerance prior therapy . pediatric information approved bristol-myers squibb company 's sprycel ( dasatinib ) tablets . however , due bristol-myers squibb company 's marketing exclusivity rights , product labeled pediatric information .",
    "contraindications": "chronic phase cml adults : 100 mg daily . ( 2 ) accelerated phase cml , myeloid lymphoid blast phase cml ph+ adults : 140 mg daily . ( 2 ) administer orally , without meal . crush , cut chew tablets . ( 2 )",
    "warningsAndPrecautions": "supplied dasatinib tablets , 20 mg white off-white , round , film-coated tablets , debossed '1741 ' one side plain side supplied follows : ndc 70710-1741-6 bottle 60 tablets child-resistant closure dasatinib tablets , 50 mg white off-white , oval , film-coated tablets , debossed '1742 ' one side plain side supplied follows : ndc 70710-1742-6 bottle 60 tablets child-resistant closure dasatinib tablets , 70 mg white off-white , round , film-coated tablets , debossed '1743 ' one side plain side supplied follows : ndc 70710-1743-6 bottle 60 tablets child-resistant closure dasatinib tablets , 80 mg white off-white , oblong , film-coated tablets , debossed '1744 ' one side plain side supplied follows : ndc 70710-1744-3 bottle 30 tablets child-resistant closure dasatinib tablets , 100 mg white off-white , oval , film-coated tablets , debossed '1745 ' one side plain side supplied follows : ndc 70710-1745-3 bottle 30 tablets child-resistant closure dasatinib tablets , 140 mg white off-white , round , film-coated tablets , debossed '1746 ' one side plain side supplied follows : ndc 70710-1746-3 bottle 30 tablets child-resistant closure storage dasatinib tablets stored 20°c 25°c ( 68ºf 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . handling disposal dasatinib antineoplastic product . follow special handling disposal procedures.1 personnel pregnant avoid exposure crushed broken tablets . dasatinib tablets consist core tablet , surrounded film coating prevent exposure healthcare professionals active substance . latex nitrile gloves appropriate disposal handling tablets inadvertently crushed broken recommended , minimize risk dermal exposure .",
    "adverseReactions": "none .",
    "indications_original": "Dasatinib tablets are indicated for the treatment of adult patients with\n                  \n                     Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.\n                     Chronic, accelerated or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.\n                     Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.\n                  \n                  \n                     Pediatric use information is approved for Bristol-Myers Squibb Company's Sprycel (dasatinib) tablets. However, due to Bristol-Myers Squibb Company's marketing exclusivity rights, this drug product is not labeled with that pediatric information.",
    "contraindications_original": "Chronic phase CML in adults: 100 mg once daily. ( 2 ) Accelerated phase CML, myeloid or lymphoid blast phase CML or Ph+ ALL in adults: 140 mg once daily. ( 2 ) Administer orally, with or without a meal. Do not crush, cut or chew tablets. ( 2 )",
    "warningsAndPrecautions_original": "How Supplied\n                     \n                  \n                  Dasatinib Tablets, 20 mg are white to off-white, round, film-coated tablets, debossed with '1741' on one side and plain on the other side and are supplied as follows:\n                  NDC 70710-1741-6 in bottle of 60 tablets with child-resistant closure\n                  Dasatinib Tablets, 50 mg are white to off-white, oval, film-coated tablets, debossed with '1742' on one side and plain on the other side and are supplied as follows:\n                  NDC 70710-1742-6 in bottle of 60 tablets with child-resistant closure\n                  Dasatinib Tablets, 70 mg are white to off-white, round, film-coated tablets, debossed with '1743' on one side and plain on the other side and are supplied as follows:\n                  NDC 70710-1743-6 in bottle of 60 tablets with child-resistant closure\n                  Dasatinib Tablets, 80 mg are white to off-white, oblong, film-coated tablets, debossed with '1744' on one side and plain on the other side and are supplied as follows:\n                  NDC 70710-1744-3 in bottle of 30 tablets with child-resistant closure\n                  Dasatinib Tablets, 100 mg are white to off-white, oval, film-coated tablets, debossed with '1745' on one side and plain on the other side and are supplied as follows:\n                  NDC 70710-1745-3 in bottle of 30 tablets with child-resistant closure\n                  Dasatinib Tablets, 140 mg are white to off-white, round, film-coated tablets, debossed with '1746' on one side and plain on the other side and are supplied as follows:\n                  NDC 70710-1746-3 in bottle of 30 tablets with child-resistant closure\n                  \n                     \n                        Storage\n                     \n                  \n                  Dasatinib tablets should be stored at 20°C to 25°C (68ºF to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].\n                  \n                     \n                        Handling and Disposal\n                     \n                  \n                  Dasatinib is an antineoplastic product. Follow special handling and disposal procedures.1\n                  \n                  Personnel who are pregnant should avoid exposure to crushed or broken tablets.\n                  Dasatinib tablets consist of a core tablet, surrounded by a film coating to prevent exposure of healthcare professionals to the active substance. The use of latex or nitrile gloves for appropriate disposal when handling tablets that are inadvertently crushed or broken is recommended, to minimize the risk of dermal exposure.",
    "adverseReactions_original": "None."
}